{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:04:44Z","timestamp":1789621484073,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.oret.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:29:01Z","timestamp":1784615341000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transient OCT Changes after High-Dose Intravitreal Topotecan for Retinoblastoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8465-2716","authenticated-orcid":false,"given":"Christina","family":"Stathopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-1050","authenticated-orcid":false,"given":"Francis L.","family":"Munier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.07.007_bib1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/bjophthalmol-2011-301016","article-title":"Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track","volume":"96","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.007_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2019.05.005","article-title":"Conservative management of retinoblastoma: challenging orthodoxy without compromising the state of metastatic grace. \u201cAlive, with good vision and no comorbidity\u201d","volume":"73","author":"Munier","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2026.07.007_bib3","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archophthalmol.2012.1983","article-title":"Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma","volume":"130","author":"Ghassemi","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.007_bib4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjophthalmol-2013-303885","article-title":"Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review","volume":"98","author":"Smith","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.007_bib5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ophtha.2016.12.015","article-title":"Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-year experience","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.07.007_bib6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ophtha.2024.04.022","article-title":"Intravitreal topotecan for vitreous seeds in retinoblastoma: a long-term review of 91 eyes","volume":"131","author":"Sen","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.07.007_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/bjophthalmol-2017-310641","article-title":"Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma","volume":"102","author":"Rao","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.007_bib8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bjophthalmol-2020-318529","article-title":"Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study","volume":"106","author":"Bogan","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.07.007_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0000000000004283","article-title":"High-dose intravitreal topotecan for recurrent retinoblastoma, subretinal seeds, and vitreous seeds","volume":"45","author":"Shields","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.07.007_bib10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.oret.2024.11.010","article-title":"Intravitreal melphalan versus topotecan for vitreous seeds in retinoblastoma: a comparative study of 64 Asian Indian eyes","volume":"9","author":"Agarwal","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.07.007_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109026","article-title":"Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: implications for retinoblastoma treatment","volume":"218","author":"Del Sole","year":"2022","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.oret.2026.07.007_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2025.100963","article-title":"In vitro stability and preclinical safety evaluation of high-dose intravitreal topotecan in rabbits: impact of dose and concentration","volume":"6","author":"Del Sole","year":"2026","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2026.07.007_bib13","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1097\/IAE.0000000000004601","article-title":"High-dose intravitreal topotecan (100 \u03bcG\/0.1 CC) as monotherapy for recurrent\/refractory intraocular retinoblastoma in seven eyes","volume":"45","author":"Vempuluru","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.07.007_bib14","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.3928\/01913913-20230110-01","article-title":"Intravitreal topotecan 90 \u03bcG for recurrent solid retinoblastoma tumors is effective and not toxic","volume":"60","author":"Abramson","year":"2023","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.oret.2026.07.007_bib15","author":"Abramson"},{"key":"10.1016\/j.oret.2026.07.007_bib16","article-title":"High-dose topotecan (90 and 180 \u03bcG) for recurrent subretinal and vitreous seeding in retinoblastoma","volume":"40","author":"Abramson","year":"2025","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.oret.2026.07.007_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/IAE.0000000000004678","article-title":"Lack of complications of high-dose intravitreal topotecan for recurrent retinoblastoma in 81 consecutive injections","volume":"46","author":"Shields","year":"2026","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.07.007_bib18","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.oret.2024.10.010","article-title":"High-dose intravitreal topotecan for perifoveal recurrence of retinoblastoma","volume":"9","author":"Woods","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.07.007_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ohc.2004.11.003","article-title":"Intraocular retinoblastoma: the case for a new group classification","volume":"18","author":"Linn Murphree","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.oret.2026.07.007_bib20","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","article-title":"Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications","volume":"96","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026003660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026003660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:45:41Z","timestamp":1789620341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026003660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"alternative-id":["S2468653026003660"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.07.007","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transient OCT Changes after High-Dose Intravitreal Topotecan for Retinoblastoma","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}